abstract |
The present application relates to non-malignant signs such as psoriasis, endometriosis, scleroderma, vascular diseases or disorders, respiratory diseases, colon polyps, or fibroadenoma using anti-ErbB2 antibodies (eg, rhuMAb2C4) The treatment method of will be described. |